Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-1501 in IgA Nephropathy
NCT05125068Phase 2Terminated
- Sponsor
- Eledon Pharmaceuticals, Inc.
- Start
- Mar 2022
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, open-label trial of tegoprubart in IgA nephropathy (IgAN) (2 arms), sponsored by Eledon Pharmaceuticals, Inc. Primary endpoints: Change in Urine Protein Creatinine Ratio at 24 weeks and Number of participants with treatment related adverse events at 100 weeks. Started Mar 2022; status: terminated.
02
Drugs
tegoprubart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05125068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125068.